Research programme: LpxC inhibitors - Forge Therapeutics
Alternative Names: FG-944; FG-LpxC; FG-LpxC LUNG; FG-LpxC UTILatest Information Update: 28 Aug 2026
At a glance
- Originator Forge Therapeutics
- Class Anti-infectives; Antibacterials; Small molecules; Urinary anti-infective agents
- Mechanism of Action LpxC inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections; Respiratory tract infections; Sexually transmitted infections; Urinary tract infections
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
- 28 Aug 2026 No recent reports of development identified for preclinical development in Respiratory-tract-infections in USA
- 28 Aug 2026 No recent reports of development identified for preclinical development in Urinary-tract-infections in USA (IV)